U.S., Feb. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07395479) titled 'A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening' on Jan. 10.
Brief Summary: This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3, etc.) in patients with advanced malignant tumors.
Study Start Date: Nov. 21, 2025
Study Type: INTERVENTIONAL
Condition:
Advanced Malignant Tumours
Intervention:
GENETIC: V001-BCMA
An in vivo CAR-T drug targeting BCMA administered intra...